Why is FDA Commissioner Marty Makary resigning?

FDA commissioner steps down after weeks of pressure

Food and Drug Administration Commissioner Marty Makary is set to resign after a short stint of roughly one year, with multiple stories indicating the decision follows weeks of mounting pressure and internal conflict around how he would carry out priorities.

The reporting describes a pattern of high-profile departure within the Trump administration, with Makary framed as the fourth high-profile departure of a member of the administration this year.

While the details of the pressure are not fully laid out in the provided excerpts, the stories connect the resignation to:

• Weeks of pressure on Makary leading up to the announcement.
• Mounting scrutiny and changing dynamics inside the FDA and the broader administration.

One excerpt characterizes Makary as having sometimes tried to advance his own principles alongside administration goals that, at times, were at odds with those principles. That tension is positioned as part of why the relationship could not be sustained.

The news also notes that the administration intends to name a next acting leader. A White House official told a news outlet that Makary’s resignation would take effect Tuesday.

Makary’s departure matters because the FDA regulates major areas of public health and has been at the center of politically salient policy debates, including those involving food and tobacco oversight and pharmaceutical decision-making. A leadership change can affect how quickly the agency moves on enforcement priorities, drug approvals, and public health messaging.

The provided set does not specify who will serve as acting commissioner or provide an official statement from Makary explaining his reasoning beyond the fact of resignation amid pressure. It also doesn’t detail the precise policy disagreements that drove the split.